20,425 Shares in Guardant Health, Inc. (NASDAQ:GH) Acquired by Edgestream Partners L.P.

Edgestream Partners L.P. acquired a new stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 20,425 shares of the company's stock, valued at approximately $870,000.

Several other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in shares of Guardant Health by 3.0% in the 4th quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock worth $368,205,000 after purchasing an additional 350,606 shares during the period. Deep Track Capital LP increased its holdings in Guardant Health by 7.0% during the 4th quarter. Deep Track Capital LP now owns 6,419,566 shares of the company's stock worth $196,118,000 after acquiring an additional 419,006 shares during the period. Two Sigma Advisers LP boosted its holdings in Guardant Health by 96.7% in the 4th quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company's stock valued at $70,742,000 after purchasing an additional 1,138,300 shares during the period. Two Sigma Investments LP grew its position in shares of Guardant Health by 38.5% during the 4th quarter. Two Sigma Investments LP now owns 1,890,714 shares of the company's stock valued at $57,761,000 after purchasing an additional 525,368 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Guardant Health in the fourth quarter worth $36,438,000. Institutional investors own 92.60% of the company's stock.

Guardant Health Stock Up 0.9%

Shares of Guardant Health stock traded up $0.39 during trading on Tuesday, reaching $46.03. 932,719 shares of the stock were exchanged, compared to its average volume of 2,263,502. The stock's fifty day moving average is $46.30 and its 200 day moving average is $44.47. The firm has a market cap of $5.70 billion, a price-to-earnings ratio of -13.58 and a beta of 1.44. Guardant Health, Inc. has a 1 year low of $20.14 and a 1 year high of $53.42.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.08. The company had revenue of $203.47 million for the quarter, compared to analysts' expectations of $189.91 million. Guardant Health's quarterly revenue was up 20.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.46) EPS. Equities analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, Director Meghan V. Joyce sold 3,337 shares of the company's stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $47.22, for a total value of $157,573.14. Following the completion of the transaction, the director directly owned 11,150 shares in the company, valued at $526,503. This represents a 23.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ian T. Clark sold 6,672 shares of the business's stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $48.38, for a total transaction of $322,791.36. Following the completion of the sale, the director owned 9,851 shares in the company, valued at approximately $476,591.38. The trade was a 40.38% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 342,300 shares of company stock worth $17,082,238. 6.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

GH has been the subject of several research analyst reports. Piper Sandler reissued an "overweight" rating and set a $60.00 price objective (up previously from $50.00) on shares of Guardant Health in a research note on Tuesday, May 6th. Scotiabank reiterated an "outperform" rating on shares of Guardant Health in a research report on Monday, May 5th. TD Securities upped their price objective on shares of Guardant Health from $56.00 to $60.00 and gave the stock a "buy" rating in a research report on Thursday, May 1st. Stephens reiterated an "overweight" rating and set a $55.00 target price on shares of Guardant Health in a research report on Wednesday, March 26th. Finally, Stifel Nicolaus boosted their price target on shares of Guardant Health from $53.00 to $60.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Twenty investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $54.45.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.